- Home
- CTMX vs ORGO Comparison
CTMX vs ORGO Comparison
Compare CTMX & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- ORGO
- Stock Information
- Founded
- CTMX 2008
- ORGO 1985
- Country
- CTMX United States
- ORGO United States
- Employees
- CTMX N/A
- ORGO N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- CTMX Health Care
- ORGO Health Care
- Exchange
- CTMX Nasdaq
- ORGO Nasdaq
- Market Cap
- CTMX 444.3M
- ORGO 384.4M
- IPO Year
- CTMX 2015
- ORGO N/A
- Fundamental
- Price
- CTMX $2.48
- ORGO $4.05
- Analyst Decision
- CTMX Strong Buy
- ORGO Buy
- Analyst Count
- CTMX 2
- ORGO 2
- Target Price
- CTMX $5.00
- ORGO $5.50
- AVG Volume (30 Days)
- CTMX 2.7M
- ORGO 1.0M
- Earning Date
- CTMX 08-07-2025
- ORGO 08-07-2025
- Dividend Yield
- CTMX N/A
- ORGO N/A
- EPS Growth
- CTMX 128.27
- ORGO N/A
- EPS
- CTMX 0.49
- ORGO N/A
- Revenue
- CTMX $147,557,000.00
- ORGO $458,760,000.00
- Revenue This Year
- CTMX N/A
- ORGO $2.62
- Revenue Next Year
- CTMX N/A
- ORGO $12.46
- P/E Ratio
- CTMX $5.11
- ORGO N/A
- Revenue Growth
- CTMX 23.81
- ORGO 5.35
- 52 Week Low
- CTMX $0.40
- ORGO $2.28
- 52 Week High
- CTMX $3.10
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- CTMX 56.59
- ORGO 68.18
- Support Level
- CTMX $2.15
- ORGO $3.59
- Resistance Level
- CTMX $2.44
- ORGO $3.69
- Average True Range (ATR)
- CTMX 0.24
- ORGO 0.20
- MACD
- CTMX -0.05
- ORGO 0.11
- Stochastic Oscillator
- CTMX 39.71
- ORGO 96.57
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.